COVID-19 Vaccine Clinical Trial
Official title:
A Parallel Group, Prospective, Randomized, Two-arm, Open-label Study to Evaluate the Immunogenicity, Safety, and Tolerability of Heterologous 3rd Boost of MVC-COV1901 in Adults With 2 Doses of ChAdOx1-nCov-19 in 3 Months and 6 Months
This primary objective of the study is to measure the anti-SARS-CoV-2 neutralizing antibody titers in adult participants in order to demonstrate the immunogenicity and safety of heterologous third-boost with MVC-COV1901, in terms of the neutralizing antibody GMTs at 28 days after the study intervention. This study also assesses the safety and tolerability of the study intervention and explores the immunogenicity by the antigen-specific immunoglobulin as well as the potential efficacy of study intervention in preventing COVID-19. This study is aimed to recruit participants at single study site in Northern Taiwan.
This a parallel group, prospective, randomized, two-arm, open-label, single-center study to be conducted in approximately 200 healthy participants aged 20 to 64 years who have had their two doses of ChAdOx1-nCov-19 (Astra Zeneca). Preparation and administration of study intervention will be performed by authorized unblinded site personnel. Eligible participants will receive MVC-COV1901 vaccine after a 3-month (Group A: < 16 weeks and ≥ 12 weeks) or 6-month (Group B: < 28 weeks and ≥ 24 weeks) interval apart from their second dose of ChAdOx1-nCov-19. The study consists of 6 on-site visits: - Day -28 to Day 1, Visit 1 (Screening) - Day 1, Visit 2 (study intervention) : randomization Group A and B Group A: - Day 1, Visit 2: treatment - Day 29 ± 3 days, Visit 3 - Day 85 ± 3 days, Visit 4 - Day 169 ± 3 days, Visit 5 Group B: - Day 1, Visit 2 - Day 85 ± 3 days, Visit 3: treatment - Day 113 ± 3 days, Visit 4 - Day 169 ± 3 days, Visit 5 ;
| Status | Clinical Trial | Phase | |
|---|---|---|---|
| Completed |
NCT05049226 -
Third Dose Vaccination With AstraZeneca or Pfizer COVID-19 Vaccine Among Adults Received Sinovac COVID-19 Vaccine
|
Phase 2 | |
| Recruiting |
NCT05998824 -
COVID-19 Vaccination Hesitancy in Adults With Sickle Cell Disease
|
N/A | |
| Active, not recruiting |
NCT05463419 -
A Phase II/III Study of PIKA Recombinant SARS-CoV-2 Vaccine as a Booster Dose.
|
Phase 2/Phase 3 | |
| Active, not recruiting |
NCT05293223 -
Phase IIB Study of Recombinant Novel Coronavirus Vaccine
|
Phase 2 | |
| Completed |
NCT04691947 -
Safety and Immunogenicity of Two Different Strengths of the Inactivated COVID-19 Vaccine ERUCOV-VAC
|
Phase 1 | |
| Completed |
NCT05288231 -
Cardiac Manifestation in Adolescent After Pfizer COVID-19 Injection in Thailand
|
||
| Completed |
NCT04546841 -
Safety and Immunogenicity Trial of Multi-peptide Vaccination to Prevent COVID-19 Infection in Adults
|
Phase 1 | |
| Terminated |
NCT04963790 -
Enabling Family Physicians to Reduce Vaccine Hesitancy and Increase Covid-19 Vaccine Uptake
|
N/A | |
| Completed |
NCT05216601 -
A Study to Evaluate the Safety, Tolerability, and Immunogenicity of MVC-COV1901 or MVC-COV1901(Beta) Against COVID-19
|
Phase 1 | |
| Completed |
NCT04566276 -
ChulaCov19 Vaccine in Healthy Adults
|
Phase 1/Phase 2 | |
| Completed |
NCT04915820 -
Iron and COVID-19 Vaccine Response
|
N/A | |
| Completed |
NCT05268679 -
Covid-19 Vaccine Response in Heart Transplant Recipients
|
||
| Completed |
NCT04898946 -
Serological Response to mRNA and Inactivated COVID-19 Vaccine in Health Care Workers in Hong Kong
|
||
| Recruiting |
NCT05869968 -
SCIVAX: Biomarkers of Immune Dysfunction and Vaccine Responsiveness in Chronic SCI
|
||
| Active, not recruiting |
NCT05197712 -
Evaluation of the Safety, Tolerability, and Reactogenicity of the Baiya SARS-CoV-2 Vax 2 Vaccine for COVID-19 Disease
|
Phase 1 | |
| Recruiting |
NCT05553743 -
Researchers at UC San Diego Are Learning About the Benefits of Human Milk and How it Influences Infant and Child Health
|
||
| Active, not recruiting |
NCT05188469 -
Study to Assess the Safety, Tolerability and Explore the Immunogenicity of EG-COVID and EG-COVARo in Healthy Adult Volunteers
|
Phase 1/Phase 2 | |
| Completed |
NCT04764422 -
Assess the Safety and Immunogenicity of NDV-HXP-S Vaccine in Thailand
|
Phase 1/Phase 2 | |
| Recruiting |
NCT04838080 -
Safety and Immunogenicity of the Inactivated Koçak-19 Inaktif Adjuvanlı COVID-19 Vaccine Compared to Placebo
|
Phase 1 | |
| Recruiting |
NCT05822219 -
Vaccine Hesitancy in Black/African Americans With Rheumatic Diseases
|
N/A |